Search

everythinglearnresearchcommunity

for

Search:↓

Best 2% Minox brand for mixing with pyrilutamide powder and retinoic acid sought. Advice on specific treatments discussed.

A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

A user is experiencing hairline recession and has started using RU58841, applying it to the temples. They are seeking advice on the appropriate dosage for this specific area.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

The user is considering switching to oral dutasteride, topical minoxidil, retinoic acid, and clobetasol for hair loss treatment, after limited regrowth with finasteride and other topicals. They are seeking a source for clobetasol, as they believe it may help with their condition.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

User discusses using C60 serum with microneedling at 1.75mm and asks if it's safe. Current routine includes daily Pyril on temples, weekly microneedling, and C60 serum on non-Pyril days.

A user is asking if a new hair product, Cypress Premium Vials Energy and Cypress Premium Shampoo Energy, could be dangerous or worsen their hair condition. The product contains various ingredients including water, alcohol, menthyl lactate, and several extracts.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

The conversation discusses creating a topical catalase solution with phosphate buffered saline, glycerin, and polysorbate 20 for hair loss treatment. The user seeks advice on preparing this solution.

Shiseido's Dermal Sheath Cup (DSC) Hair Multiplication treatment is now available in Japan. Users discuss the treatment's availability and cost.

The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.

The conversation is about finding a source for Alfatradiol 0.1% as most available products are 0.025%. A suggestion was made to use four times the dosage of the 0.025% product.

The conversation discusses using GHK-Cu for hair loss, with one user suggesting subcutaneous administration for better control. The effectiveness of topical application is questioned due to a lack of reliable reviews.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

The conversation is about accessing and purchasing RU58841 or Pyrilutamide for hair loss treatment, with mentions of alternatives like Breezula. Users discuss price differences in various countries and suggest websites like rudirect.com for purchasing.

The conversation is about baricitinib, a medicine that can help with hair loss, and why it isn't more popular or widely discussed. No specific experiences with the treatment were shared.

Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.

The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.

User wants to add RCP to regimen and asks if it can be applied with topical minoxidil and/or finasteride at night.

User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.

People are discussing the group buy and availability of KX-826 for hair loss treatment, with shipments expected around March-April. There is interest in finding more information and joining future group buys.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.

Hair loss treatments discussed: GT 20029, Pyrilutamide, Minoxidil, Finasteride, and Dutasteride. Some believe Dutasteride will replace Finasteride.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.